ABSTRACT
Drug Development .........................................................................................49 4.3 Class Discovery and Class Distinction in Surrogate Tissue Profiling
Studies ............................................................................................................50 4.4 Relevance of Peripheral Blood in Assessment of Patients with Solid
Tumors............................................................................................................52 4.5 Pharmacogenomic Analysis of PBMCs in Renal Cell Carcinoma: A
Case Study......................................................................................................54 4.5.1 Disease-Associated Transcripts in PBMCs of Patients with
Renal Cancer ......................................................................................54 4.5.2 Outcome-Correlated Patterns in Pretreatment PBMCs of
Patients with RCC..............................................................................57 4.6 Other Surrogate Tissue Profiling Studies in Oncology.................................57 4.7 Issues and Caveats with PBMC Profiling in Oncology Studies ...................59 4.8 Summary ........................................................................................................60 Acknowledgments....................................................................................................60 References................................................................................................................61
